Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Encouraged by Scientific Data; Sigma-1 Receptor Agonist is Potentially Disease-Modifying
Angela Cenci and colleagues from the Departments of Experimental Medical Science and Clinical Sciences projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Successfully Closes $10M Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Announces $10M Private Placement of Convertible Debentures
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS
Most people with ALS die from respiratory failure within three to five years from the onset of symptoms projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Agreement with the Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS
About Alzheimer’s Disease and Other Disorders of Cognitive Impairment Today there is significant unmet medical Healthcare costs associated with the epidemic of Alzheimer’s, including nursing home care, continue to projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Clinical Design Expert to Scientific Advisory Board
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Alzheimer's Industry Leader to Scientific Advisory Board
Gold served as the Chief Medical Officer of Allon Therapeutics, where he led a large pan-US and European projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex CEO to Participate in Brean Capital 2013 Life Sciences Summit
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Announces Expansion of Scientific Advisory Board
He is Associate Professor of Pathology and Cell Biology at the Columbia University Medical Center and Fellowship” (Georgetown University), the “Anna Villa Rusconi Foundation Prize” (Italy), the “INSERM Poste projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of AD
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
